A non-invasive system for delivering neural growth factors across the blood-brain barrier: A review

Reviews in the Neurosciences

Volumn 9, Issue 1, 1998, Pages 31-55

  Granholm, Ann Charlotte ^a,g   Albeck, David ^a   Bäckman, Cristina ^a   Curtis, Maria ^a   Ebendal, Ted ^b   Friden, Phil ^d   Henry, Michael ^a   Hoffer, Barry ^e   Kordower, Jeffrey ^f   Rose, Gregory M ^a   Söderström, Stine ^b   Bartus, Raymond T ^c  

^a UNIVERSITY OF COLORADO   (United States)

^b UPPSALA UNIVERSITY   (Sweden)

^c ALKERMES INC   (United States)

^d Periodontix Inc   (United States)

^e NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^f RUSH UNIVERSITY MEDICAL CENTER   (United States)

^g UNIVERSITY OF COLORADO   (United States)

Author keywords

Acetylcholine; Blood brain barrier; Cholinergic; Drug delivery; Forebrain septal nuclei; Macromolecules; Neurotrophins; Transferrin receptors; Transplantation

Indexed keywords

NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; RECEPTOR ANTIBODY; TRANSFERRIN RECEPTOR;

AMNESIA; BLOOD BRAIN BARRIER; CHOLINERGIC NERVE CELL; DRUG DELIVERY SYSTEM; FOREBRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; SEPTUM NUCLEUS;

EID: 13144282770     PISSN: 03341763     EISSN: None     Source Type: Journal    
DOI: 10.1515/REVNEURO.1998.9.1.31     Document Type: Review

References (154)

1. Aisen P, Listowsky I. Iron transport and storage proteins. Ann Rev Biochem 1980; 49: 357-393.
2. Albeck DS, Rose GM, Veng L, Bartus R, Granholm A-Ch. Electrophysiological effects of OX-26-NGF on medial septal neurons. Soc Neurosci Abst 1996; 22: 752.
3. Albeck DS, Hoffer BJ, Quissell D, Sanders LA, Zerbe G, Granholm A-ChE. A non-invasive transport system for GDNF across the blood-brain barrier. NeuroReport 1997; 7: 2293-2298.
4. Alberch J, Perez-Navarro E, Arenas E, Marsal J. Involvement of nerve growth factor and its receptor in the regulation of the cholinergic function in aged rats. J Neurochem 1991; 57: 1483-1487.
5. Altavista MC, Bentivoglio AR, Crociani P, Rossi P, Albanese A. Age-dependent loss of cholinergic neurons in the basal ganglia of rats. Brain Res 1988; 455: 177-181.
6. Altavista MC, Rossi P, Bentivoglio AR, Crociani P, Albanese A. Aging is associated with diffuse loss of forebrain cholinergic neurons. Brain Res 1990; 508: 51-59.
7. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with polysorbe 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res 1997; 14: 325-328.
8. Arendt T, Bigl V, Tennstedt A, Arendt A. Correlation between cortical plaque count and neuronal loss in the nucleus basalis in Alzheimer's disease. Neurosci Lett 1984; 48: 81-85.
9. Armstrong DM, Sheffield R, Buzsaki G, Chen KS, Hersh LB, Wearing BG, Gage FH. Morphological alterations of choline acetyltransferase-positive neurons in the basal forebrain of aged behaviorally characterized Fischer 344 rats. Neurobiol Aging 1993; 14: 457-470.
10. Baba T, Black KL, Ikezaki K, Chen K, Becker DP. Intracarotid infusion of leukotriene C4 selectively increases blood-brain barrier permeability after focal ischemia in rats. J Cereb Blood Flow Metabol 1991; 11: 638-643.
11. Bartus. RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 408-417.
12. Bartus RT, Flicker C, Dean RL, Pontecorvo M, Figueiredo J, Fisher SK. Selective memory loss following nucleus basalis lesions: Long term behavioral recovery despite persistent cholinergic deficiencies. Pharm Biochem Behav 1985; 23: 125-135.
13. Bartus RT, Elliot PJ, Dean RL, Hayward NJ, Nagle TL, Huff MR, Snodgrass PA, Blunt DG. Controlled modulation of BBB permeability using the bradykinin agonist, RMP-7. Exp Neurol 1996; 142: 14-28.
14. Bartus RT, Elliott P, Hayward N, Dean R, Fisher S. Permeability of the BBB by the B2 agonist RMP-7: Evidence for a sensitive, autoregulated, receptor-mediated system. Immunopharmacology 1996; 33: 270-278.
15. Bartus RT, Dean RL, Abelleira S, Charles V, Kordower JH. Dissociation of p75 receptors and nerve growth factor neurotrophic effects: lack of p75 immunoreactivity in striatum following physical trauma, excitotoxicity, and NGF administration. Restorative Neurol Neurosci 1996; 10: 49-59.
16. Beigon A, Greenberger V, Segal M. Quantitative histochemistry of brain acetylcholine esterase and learning rate in aged rat. Neurobiol Aging 1986; 7: 215-217.
17. Bickel U, Yoshikawa T, Landdaw EM, Faull KF, Pardridge WM. Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery. Proc Natl Acad Sci USA 1993; 90: 2618-2622.
18. Blasberg RGC, Patlak C, Fenstermacher JD. Intrathecal chemotherapy: brain tissue profiles after ventriculocisternal perfusion. J Pharmacol Exp Therap 1975; 195: 73-83.
19. Bothwell M. Keeping track of neurotrophin receptors. Cell 1991; 65: 915-918.
20. Bothwell M. Functional interactions of neurotrophins and neurotrophin receptors. Ann Rev Neurosci 1995; 18: 223-253.
21. Broadwell RD, Charlton HM, Ebert P, Hickey W, Shirazi Y, Villegas J, Wolf A. Allografts of CNS tissue possess a blood-brain barrier. II. Angiogenesis in solid tissue and cell suspension grafts. Exp Neurol 1991; 112: 1-28.
22. Broadwell RD, Baker BJ, Ebert P, Hickey WF, Villegas J. Intracerebral grafting of solid tissues and cell suspensions: the blood-brain barrier and host immune response. Prog Brain Res 1992; 91: 95-102.
23. Broadwell RD, Baker-Cairns BJ, Friden PM, Oliver C, Villegas JC. Transcytosis of protein through the mammalian cerebral epithelium and endothelium. III. Receptor-mediated transcytosis through the blood-brain barrier of blood-borne transferrin and antibody against the transferrin receptor. Exp Neurol 1996; 142: 47-65.
24. Burton PS, Conradi RA, Ho NF, Hilgers AR, Borchardt RT. How structural features influence the biomembrane permeability of peptides. J Pharm Sci 1996; 85: 1336-1340.
25. Bäckman C, Biddle PT, Ebendal T, Friden PM, Gerhardt GA, Henry MA, Mackerlova L, Söderström S, Strömberg I, Walus L, Hoffer BJ, Granholm A-Ch. Effects of transferrin receptor antibody-NGF conjugate on young and aged septal transplants in oculo. Exp Neurol 1995; 132: 1-15.
26. Bäckman C, Rose GM, Hoffer BJ, Henry MA, Bartus RT, Friden P, Granholm A-Ch. Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J Neurosci 1996; 16: 5437-5442.
27. Bäckman C, Rose GM, Bartus RT, Hoffer BJ, Mufson EJ, Granholm A-Ch. Carrier mediated delivery of NGF: alterations in basal forebrain neurons in aged rats revealed using antibodies against low and high affinity NGF receptors. J Comp Neurol 1997; 387: 1-11.
28. Camarata PJ, Suryanarayanan R, Turner DA, Parker RG, Ebner TJ. Sustained release of nerve growth factor from biodegradable polymer microspheres. Neurosurgery 1992; 30: 313-319.
29. Charles V, Mufson EJ, Friden PM, Bartus RT, Kordower JH. Atrophy of cholinergic basal forebrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Res 1996; 728: 193-203.
30. Chen KS, Gage FH. Somatic gene transfer of NGF to the aged brain: behavioral and morphological amelioration. J Neurosci 1995; 15: 2819-2825.
31. Chen XL, Roisen FJ, Gupta M. The effect of prior in vitro exposure of donor cells to trophic factors in neurotransplantation. Exp Neurol 1996; 138: 64-72.
32. Conner JM, Varon S. Nerve growth factor influences the distribution of sympathetic sprouting into the hippocampal formation by implanted superior cervical ganglia. Exp Neurol 1994; 130: 15-23.
33. 125I]nerve growth factor by cholinergic neurons and down-regulated TrkA expression in the medial septum of aged rats. Neuroscience 1994; 62: 625-629.
34. Curtis M, Henry MA, Hoffer BJ, Bartus RT, Granholm A-Ch. Light and electron microscopic localization of OX-26-immunoreactivity in brain. Abstr Neurosci 1995.
35. Davies P. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 1979; 171: 319-327.
36. Davies P. Is it possible to design rational treatment for the symptoms of Alzheimer's disease? Drug Dev Res 1985; 5: 69-75.
37. Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, Edge A, Penney D, Kassissieh S, Dempsey P, Isacson O. Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease. Nature Med 1997; 3: 350-353.
38. Dean RL, Stackman R, Abelleira SM, Carroll RM, Kordower JH, Walsh T, Bartus RT. NGF conjugate ameliorates basal forebrain cholinergic hypofunction induced by AF64A. Abstr Neurosci 1994; 20: 1103.
39. Decker M. The effects of aging on hippocampal and cortical projections of the forebrain cholinergic system. Brain Res 1987; 12: 423-438.
40. Drackmann DA, Leavitt J. Human memory and the cholinergic system: a relationship to aging? Arch Neurol 1974; 30: 113-121.
41. Duffy KR, Pardridge WM. Blood-brain barrier transcytosis of insulin in developing rabbits. Brain Res 1987; 420: 32-38.
42. Duffy KR, Pardridge WM, Rosenfeld RG. Human blood-brain barrier insulin-like growth factor receptor. Metabolism 1988; 37: 136-140.
43. Ebendal T, Olson L, Seiger Å, Belew M. Nerve growth factors in chick and rat tissues. In: Black I, ed. Cellular and Molecular Biology of Neuronal Development. New York: Plenum Press, 1984; 231-242.
44. Ebendal T. NGF in CNS: Experimental data and clinical implications. Prog Growth Factor Res 1989; 1: 143-159.
45. Ebendal T. Use of collagen gels to bioassay nerve growth factor activity. In: Rush RA, ed. Nerve Growth Factors. IBRO Handbook Series: Methods in Neurosciences, Vol 12. Chichester: John Wiley, 1989; 81-93.
46. Ebendal T. Function and evolution of the NGF family and its receptors. J Neurosci Res 1992; 32: 461-470.
47. Ebendal T, Lönnerberg P, Pei G, Kylberg A, Kullander K, Persson H, Olson L. Engineering cells to secrete growth factors. J Neurol 1994; 242 (Suppl 1): S5-S7.
48. Ehlers MD, Kaplan DR, Price DL, Koliatsos VE. NGF-stimulated tramsport of trkA in the mammalian nervous sytem. J Cell Biol 1995; 130: 149-156.
49. Emerich DF, Winn SR, Hantraye PM, Peschanski M, Chen EY, Chu Y, McDermott P, Baetge EE, Kordower JH. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease. Nature 1997; 386: 395-399.
50. Eriksdotter-Nilsson M, Skirboll S, Ebendal T, Hersh L, Grassi J, Massoulie J, Olson L. NGF treatment promotes development of basal forebrain tissue grafts in the anterior chamber of the eye. Exp Brain Res 1989; 7: 1-10.
51. Fisher W, Wictorin K, Björklund A, Williams LR, Varon S, Gage FH. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by NGF. Nature (Lond.) 1987; 329: 53-61.
52. Fisher W, Gage FH, Björklund A. Degenerative changes in forebrain cholinergic nuclei correlate with cognitive impairments in aged rats. Eur J Neurosci 1989; 1: 34-45.
53. Fisher W, Björklund A, Chen K, Gage FH. NGF improves spatial memory in aged rodents as a function of age. J Neurosci 1991; 11: 1889-1906.
54. Fisher W, Chen KS, Gage FH, Björklund A. Progressive decline in spatial learning and integrity of forebrain cholinergic neurons in rats during aging. Neurobiol Aging 1992; 13: 2-23.
55. Fisher W, Sirevaag A, Wiegand SJ, Lindsay RM, Björklund A. Reversal of spatial memory impairments in aged rats by nerve growth factor and neurotrophins 3 and 4-5 but not brain derived neurotrophic factor. Proc Natl Acad Sci USA 1994; 91: 8607-8611.
56. Flicker C, Deal RL, Watkins DL, Fisher SK, Bartus RT. Behavioral and neurochemical effects following neurotoxic lesions of major cholinergic input to the cerebral cortex in the rat. Pharm Biochem Behav 1983; 18: 973-981.
57. Friden PM, Walus LR, Musso GF, Taylor MA, Malfroy B, Starzyk RM. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 1991; 88: 4771-4775.
58. Friden PM, Walus LR, Watson P, Doctorow SR, Kozarich JW, Backman C, Bergman H, Hoffer B, Bloom F, Granholm A-Ch. Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 1993; 259: 373-377.
59. Friden PM. Receptor-mediated transport of therapeutics across the blood-brain barrier. Neurosurgery 1994; 35: 294-298.
60. Friden PM, Olson TS, Obar R, Walus LR, Putney SD. Characterization, receptor mapping and blood-brain barrier transcytosis of antibodies ot the human transferrin receptor. J Pharm Exp Therap 1996; 278: 1491-1498.
61. Friedman WJ, Ibanez CF, Hallböök F, Persson H, Cain LD, Dreyfus CF, Black IB. Differential actions of neurotrophins in the locus coeruleus and basal forebrain. Exp Neurol 1993; 119: 72-78.
62. Galpem WR, Matthews RT, Beal MF, Isacson O. NGF attenuates 3-nityrosine formation in a 3-NP model of Huntington's disease. NeuroReport 1996; 7: 2639-2642.
63. Gash DM, Zang Z, Ovadia A, Cass WA, Yi A, Simmerman L, Russell D, Martin D, Lapchak PA, Collins F, Hoffer BJ, Gerhardt, GA. Functional recovery in Parkinsonian monkeys treated with GDNF. Nature 1996; 380: 252-255.
64. Giometti B, Bozza F, Argentiero V, Pagni GP, Piccinno MG, Tavolato B. Transferrin receptors in rat central nervous system. An Immunocytochemical study. J Neurol Sci 1990; 98: 81-90.
65. Gnahn H, Hefti F, Heumann R, Schwab ME, Thoenen H. NGF-mediated increase of choline acetyl-transferase (ChAT) in the neonatal rat forebrain: evidence for a physiological role of NGF in the brain? Dev Brain Res 1983; 9: 45-52.
66. Godfrey EW, Shooter EM. Nerve growth factor receptors on chick embryo sympathetic ganglion cells: Binding characteristics and development. J Neurosci 1988; 6: 2543-2550.
67. Granholm A-Ch. Hippocampal transplants in oculo: A model for establishment of isolated circuits. In: Cohn M, ed. Methods in Neuroscience, Vol. 7. 1991; 327-345.
68. Granholm A-ChE, Backman C, Bloom F, Ebendal T, Gerhardt GA, Hoffer B, Mackerlova L, Olson L, Söderström S, Walus LR, Friden PM. NGF and anti-transferrin receptor antibody conjugate: short and long-term survival of cholinergic neurons in intraocular septal transplants. J Pharm Exp Ther 1994; 268: 448-459.
69. Granholm A-Ch, Biddle PT, Backman C, Ebendal T, Gerhardt GA, Hoffer BJ, Mackerlova L, Olson L, Söderström S, Walus L, Friden P. Peripheral administration of nerve growth factor conjugated to an anti-transferrin receptor antibody increases cholinergic neuron survival in intraocular forebrain transplants. Meth Neurosci 1994; 21: 71-92.
70. Granholm A-Ch, Curtis M, Diamond DM, Branch BJ, Heman KL, Rose GM. Development of an intact blood-brain barrier in brain tissue transplants is dependent on the site of transplantation. Cell Transpl 1996; 5: 305-314.
71. Gregoriadis G, Senior J, Wolff B, Kirby MC. Targeting of liposomes to accessible cells in vivo. Ann NY Acad Sci 1985; 446: 319-340.
72. Hampstead BI, Schleiter LS, Chao MV. Expression of functional nerve growth factor receptors after gene transfer. Science 1989; 243: 373-375.
73. Hartikka J, Hefti H. Comparison of nerve growth factor's effects on development of septum, striatum and nucleus basalis cholinergic neurons in vitro. J Neurosci Res 1988; 21: 352-364.
74. Hatanaka H, Tsukui S, Nihonmatsu I. Septal cholinergic neurons from postnatal rat can survive in the dissociated culture conditions in the presence of nerve growth factor. Neurosci Lett 1987; 70: 85-90.
75. Hefti F. Nerve growth factor promotes survival of septal cholinergic neurons after fimbrial transection. J Neurosci 1986; 6: 2155-2166.
76. Hefti F, Will B. Nerve growth factor is a neurotrophic factor for forebrain cholinergic neurons: implications for Alzheimer's disease? J Neural Transm 1987; 24 (Suppl): 309-315.
77. Hefti F, Mash DC. Localization of nerve growth factor receptors in the normal human brain and in Alzheimer's disease. Neurobiol Ageing 1989; 10: 75-87.
78. Henriksson BG, Söderström S, Gower AJ, Ebendal T, Winblad B, Mohammed AH. Hippocampal nerve growth factor levels are related to spatial learning ability in aged rats. Behav Brain Res 1992; 48: 15-20.
79. Hisanaga K, Tsukui H, Takei N, Hatanaka H. Transplantation of fetal and early postnatal rat septal cholinergic neurons cultured in serum-free and serum-containing medium with nerve growth factor. Brain Res 1988; 475: 349-355.
80. Hoffer BJ, Leenders KL, Young D, Gerhardt G, Zerbe GO, Bygdeman M, Seiger Å, Olson L, Strömberg I, Freedman R. Eighteen-month course of two patients with grafts of fetal dopamine neurons for severe Parkinsons disease. Exp Neurol 1992; 118: 243-252.
81. Holtzman DM, Li Y, Parada L-F, Kinsman S, Chen CK, Valleta JS, Zhou J, Long JB, Mobley WC. p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trkA gene expression is induced by NGF. Neuron 1992; 9: 465-478.
82. Honegger P, Lenoir D. Nerve growth factor (NGF) stimulation of cholinergic telencephalic neurons in aggregating cell cultures. Dev Brain Res 1982; 3: 229-238.
83. Huebers HA, Finch CA. The physiology of transferrin and transferrin receptors. Physiol Rev 1987; 67: 520-582.
84. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 1996; 93: 14164-14169.
85. Inamura T, Nomura T, Bartus RT, Black KL. Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors. J Neurosurg 1994; 81: 752-758.
86. Jeffries WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature (Lond.) 1984; 312: 162-163.
87. Jing S, Tapley P, Barbacid M. Nerve growth factor mediates signal transduction through trk homodimer receptors. Neuron 1992; 9: 1067-1079.
88. Johansson BB, Nordbor C, Westergren I. Neuronal injury after a transient opening of the blood-brain barrier: modifying factors. In: Johansson BB, Owman Ch, Widner H, eds. Pathophysiology of the Blood-Brain Barrier. Amsterdam: Elsevier Science Publishers, 1990; 145-157.
89. Kaddis FG, Clarkson ED, Weber MJ, Vandenbergh DJ, Donovan DM, Mallet J, Horellou P, Uhl GR, Freed CR. Intrastriatal grafting of Cos cells stably expressing human aromatic L-amino acid decarboxylase: neurochemical effects. J Neurochem 1997; 68: 1520-1526.
90. Kang YS, Pardridge WM. Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. Pharm Res 1994; 11: 1257-1264.
91. 3H]biotin bound to different avidin analogues. J Drug Targeting 1995; 3: 159-165.
92. Kaplan DR, Stephens RM. Neurotrophin signal transduction by the trk receptor. J Neurobiol 1994; 25: 1404-1417.
93. Koh S, Loy R. Age-related loss of NGF sensitivity in rat basal forebrain neurons. Brain Res 1988; 440: 396-401.
94. Koh S, Chang P, Collier TJ, Loy R. Loss of NGF receptor immunoreactivity in basal forebrain neurons of aged rats: correlation with spatial memory impairment. Brain Res 1989; 498: 397-404.
95. Koliatsos VE, Clatterbuck RE, Nauta HJW, Knusel B, Burton LE, Hefti FF, Mobley WC, Price DL. Human nerve growth factor prevents degeneration of basal forebrain cholinergic neurons in primates. Ann Neurol 1991; 30: 831-840.
96. Kordower JH, Mufson EJ, Granholm A-Ch, Hoffer B, Friden PM. Delivery of trophic factors to the primate brain. Exp Neurol 1993; 124: 21-30.
97. Kordower JH, Charles V, Bayer R, Bartus RT, Putney S, Walus LR, Friden PM. Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington's disease. Proc Natl Acad Sci USA 1994; 91: 9077-9080.
98. Kudo Y, Shiosaka S, Matsuda M, Tohyama M. An attempt to cause selective loss of cholinergic neurons in the basal forebrain of the rat: a new animal model of Alzheimer's disease. Neurosci Lett 1989; 102: 125-130.
99. Kumagai AK, Eisenberg J, Pardridge WM. Absorptive-mediated endocytosis of cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J Biol Chem 1989; 262: 15214-15219.
100. Levi-Montalcini R. Developmental neurobiology and the natural history of nerve growth factor. Ann Rev Neurosci 1982; 5: 341-362.
101. Li Y, Holtzman DM, Kromer LF, Kaplan DR, Chua-Couzens J, Clary DO, Knusel B, Mobley WC. Regulation of trkA and Chat expression in developing rat basal forebrain: eveidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. J Neurosci 1995; 15: 2888-2905.
102. Loy R, Lachyankar MB, Condon PJ, Poluha DK, Ross AH. Retrograde axonal transport and lesion-induced upregulation of the TrkA high-affinity NGF receptor. Exp Neurol 1994; 130: 377-386.
103. Lärkfors L, Ebendal T, Whittemore SR, Persson H, Hoffer B, Olson L. Decreased level of nerve growth factor (NGF) and its messenger RNA in the aged rat brain. Mol Brain Res 1987; 3: 55-60.
104. Markowska AL, Koliastos VE, Breckler SJ, Price DL, Olton DS. Human nerve growth factor improves spatial memory in aged but not in young rats. J Neurosci 1994; 14: 4815-4824.
105. Markowska AL, Price D, Koliatsos VE. Selective effects of nerve growth factor on spatial recent memory as assessed by a delayed nonmatching-to-position task in the water maze. J Neurosci 1996; 16: 3541-3548.
106. Markram H, Segal M. Regional changes in NGF receptor immunohistochemical labeling in the septum of the aged rat. Neurobiol Aging 1990; 11: 481-484.
107. Martinez-Serrano A, Fischer W, Soderstrom S, Ebendal T, Björklund A. Long term functrional recovery from age-induced spatial memory impairments by nerve growth factor gene transfer to the rat basal forebrain. Proc Natl Acad Sci USA 1996; 93: 6355-6360.
108. McGrath JP, Cao X, Schutz A, Lynch P, Ebendal T, Coloma MJ, Morrison SL, Putney SD. B Bifunctional fusion between nerve growth factor and a transferrin receptor antibody. J Neurosci Res 1997; 47: 123-133.
109. McKinney M, Coyle J, Hedereen JC. Topographical analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system. J Comp Neurol 1983; 217: 103-121.
110. Menei P, Boisdron-Celle M, Croue A, Guy G, Benoit JP. Effect of stereotactic implantation of biodegradable 5-fluorouracil-loaded microspheres in healthy and C6 glioma-bearing rats. Neurosurgery 1996; 39: 123-124.
111. Mesulam M-M, Mufson EJ, Wainer BH, Levey AI. Central cholinergic pathways in the rat: an overview based on alternative nomenclature (Ch1-Ch6). Neuroscience 1983; 10: 1185-1204.
112. Mufson EJ, Conner JM, Kordower JH. Nerve growth factor in Alzheimer's disease: Defective retrograde transport to nucleus basalis. NeuroReport 1995; 6: 1063-1066.
113. Mufson EJ, Kroin JS, Liu YT, Sobreviela T, Penn RD, Miller JA, Kordower JH. Intrastriatal and intraventricular infusion of brain-derived neurotrophic factor in the cynomologous monkey: distribution, retrograde transport and co-localization with substantia nigra dopamine-containing neurons. Neuroscience 1996; 71: 179-191.
114. Mufson EJ, Lavine N, Jaffar S, Kordower JH, Quirion R, Saragovi HU. Reduction in p140-TrkA receptor protein within the nucleus basalis and cortex in Alzheimer's disease. Exp Neurol 1997; 146: 91-103.
115. Neuwelt EA, Rapoport SI. Modification of the blood-brain barrier in the chemotherapy of malignant brain tumors. Fed Proc 1984; 43: 214-219.
116. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends in Neurosci 1997; 19: 102-109.
117. Olson L, Seiger Å, Strömberg I. Intraocular transplantation in rodents. A detailed account of procedure and examples of its use in neurobiology with special reference to brain tissue grafting. In: Fedoroff S, Hertz L, eds. Advances in Cellular Neurobiology, Vol. 4. New York: Academic Press, 1983; 407-441.
118. Olson L, Backlund E-O, Ebendal T, Freedman R, Hamberger B, Hansson P, Hoffer B, Lindblom U, Meyerson B, Strömberg I, Sydow O, Seiger Å. Intraputamial infusion of nerve growth factor to support adrenal medullary autografts in Parkinson's disease: one. year follow up of first clinical trial. Arch Neurol 1991; 48: 373-381.
119. IIC-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient. J Neural Transmission 1992; 4: 79-95.
120. Parada LF, Tsoulfas P, Tessarollo L, Blair J, Reid SW, Soppet D. The Trk family of tyrosine kinases: receptors for NGF-related neurotrophins. Cold Spring Harbor Symp Quant Biol 1992; 57: 43-51.
121. Pardridge WM, Triguero D, Buciak JL. Transport of histone through the blood-brain barrier. J Pharmacol Exp Therap 1989; 251: 821-826.
122. Pardridge WM, Buciak JL, Friden PM. Selective transport of an antitransferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Therap 1991; 259: 66-70.
123. Pardridge WM. Recent developments in peptide drug delivery to the brain. Pharmacol Toxicol 1992; 71: 3-10.
124. Pardridge WM, Kang YS, Buciak JL. Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery. Pharmaceut Res1994; 11: 738-746.
125. Pardridge WM, Boado RJ, Kang YS. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the the blood-brain barrier in vivo. Proc Natl Acad Sci USA 1995; 92: 5592-5596.
126. Perry EK, Tomlinson BE, Blessed G, Perry RH, Cross AJ, Crow TJ. Correlation of cholinergic abnormalities with senile plaques and mental test scores in senile dementia. Br Med J 1978; 2: 1457-1459.
127. Petty BG, Cornblath DR, Adornato BT, Chaudhry V, Flexner C, Wachsman M, Sinicropi D, Burton LE, Peroutka J. The effects of systemically administered recombinant human nerve growth factor in healthy human subjects. Ann Neurol 1994; 36: 244-246.
128. Podulso JF, Curran GL. Permeability at the blood-brain barrier and blood-nerve barriers of the neurotrophic factors: NGF, CNTF, NT-3, BDNF. Molecular Brain Res 1996; 36: 280-286.
129. Price ML, Hoffer BJ, Granholm A-Ch. Effects of GDNF on fetal septal forebrain transplants in oculo. Exp Neurol 1996; 141: 181-189.
130. Saffran BN. Should intracerebroventricular nerve growth factor be used to treat Alzheimer's disease? Perspect Biol Med 1992; 35: 471-486.
131. 125I-labeled beta-amyloid peptide A beta 1-40 through the blood-brain barrier and binding to Alzheimer disease amyloid of the A beta 1-40/vector complex. Proc Natl Acad Sci USA 1995; 92: 10227-10231.
132. Sanovich E, Bartus RT, Friden PM, Dean RL, Le HQ, Brightman MW. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995; 705: 125-135.
133. Scali C, Casamenti F, Pazzagli M, Bartollini L, Pepeu G. Nerve growth factor increases extracellular acetylcholine levels in the parietal cortex and hippocampus of aged rats and restores object recognition. Neurosci Lett 1994; 170: 117-120.
134. Seiger Å, Nordberg A, von Holst H, Bäckman L, Ebendal T, Alafuzoff I, Amberla K, Hartvig A, Lilja A. Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy. Behav Brain Res 1993; 57: 255-261.
135. Seiler M, Schwab ME. Specific retrograde transport of nerve growth factor receptor (NGF) from neocortex to nucleus basalis in the rat. Brain Res 1984; 300: 33-39.
136. Shin SU, Friden P, Moran M, Morrison SL. Functional properties of antibody insulin-like growth factor fusion proteins. J Biol Chem 1994; 269: 4979-4985.
137. Shin SU, Friden P, Moran M, Olson T, Kang YS, Pardridge WM, Morrison SL. Transferrin-antibody fusion proteins are effective in brain targeting. Proc Natl Acad Sci USA 1995; 92: 2820-2824.
138. Shitaka Y, Saito H. The effect of basic fibroblasts growth factor (bFGF) and nerve growth factor (NGF) on the survival of septal neurons transplanted to the third ventricle in rats. Japanese J Pharm 1994; 64: 27-33.
139. Sobreviela T, Clary DO, Reichardt LF, Brandabur MM, Kordower JH, Mufson EJ. TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin. J Comp Neurol 1994; 350: 587-611.
140. Spellerberg B, Prasad S, Cabellos C, Burroughs M, Cahill P, Tuomanen E. Penetration of the blood-brain barrier: enhancement of drug delivery and imaging by bacterial glycopeptides. J Exp Med 1995; 182: 1037-1043.
141. Steininger TL, Wainer BH, Klein R, Barbacid M, Palfrey HC. High affinity nerve growth factor receptor (trkA) immunoreactivity is localized in cholinergic neurons of the basal forebrain and striatum in the adult rat brain. Brain Res 1993; 612: 330-335.
142. Söderström S, Hallböök CF, Ibanez CF, Persson H, Ebendal T. Recombinant human b-nerve growth factor (NGF): Biological activity and properties in an enzyme immunoassay. J Neurosci Res 1990; 27: 665-677.
143. Takada Y, Vestica DT, Greig NH, Purdon D, Rapoport SI, Smith QR. Rapid high-affinity transport of a chemotherapeutic amino acid across the blood-brain barrier. Cancer Res 1992; 52: 2191-2196.
144. Thoenen H, Edgar D. Neurotrophic factors. Science 1985; 229: 238-242.
145. Triguero DJ, Buciak B, Yang J, Pardridge WM. Blood-brain barrier transport of cationized immunoglobulin G. Enhanced delivery compared to native protein. Proc Natl Acad Sci USA 1989; 86: 4761-4765.
146. Tsuzuki N, Hama T, Hibi T, Konishi R, Futaki S, Kitagawa K. Adamantane as a brain-directed drug carrier for poorly absorbed drug: anti-nociceptive effects of [D-Ala2] leu-enkephalin dervatives conjugated with 1-adamantaene moiety. Biochem Pharmacol 1991; 41: R5-R8.
147. Tuszynski MH, Roberts J, Senut MCUHS, Gage FH. Gene therapy in the adult primate brain: intraparenchymal grafts of cells genetically modified to produce nerve growth factor prevent cholinergic neuronal degeneration. Gene Therapy 1996; 3: 305-314.
148. Verdi JM, Birren SJ, Ibanez CF, Persson H, Kaplan DF, Benedetti M, Chao MV, Anderson DJ. p75LNGFR regulates Trk signal transduction and NGF-induced neuronal differentiation in MAH cells. Neuron 1994; 12: 733-745.
149. Wainer BH, Levey AI, Mufson EF, Mesulam MM. Cholinergic systems in mammalian brain identified with antibodies directed against cholinergic acetyltransferase. Neurosci Int 1984; 6: 163-182.
150. Walus LR, Pardridge WM, Starzyk RM, Friden PM. Enhanced uptake of rsCD4 across the rodent and primate blood-brain barrier after conjugation to anti-transferrin receptor antibodies. J Pharm Exp Therap 1996; 277: 1067-1075.
151. Williams LR, Varon S, Peterson GM, Wictorin K, Fisher W, Björklund A, Gage FH. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. Proc Natl Acad Sci USA 1986; 83: 9231-9235.
152. Wu D, Pardridge WM. Central nervous system pharmacologic effect in concious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J Pharm Exp Ther 1996; 279: 77-83.
153. Yankner BA, Shooter EM. The biology and mechanism of action of nerve growth factor. Ann Rev Biochem 1982; 51: 845-868.
154. Zunkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, Saris SC, Wright DC, Kammerer W, Patronas NJ, Dedrick RL, Herscovitch P, Oldfield EH. Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 1996; 85: 1056-1065.